SAFETY AND EFFICACY OF AMBISOME VS CONVENTIONAL AMPHOTERICIN B IN THE TREATMENT OF PATIENTS WITH SUSPECTED OR CONFIRMED MYCOSIS
Phase 4
Completed
- Conditions
- Mycosis - an invasive fungal infectionsInfection - Studies of infection and infectious agents
- Registration Number
- ACTRN12605000596606
- Lead Sponsor
- Dr. Michael Whitby (Princess Alexandra Hsp, QLD)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 104
Inclusion Criteria
Highly suspected or confirmed invasive fungal infection.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint is the rate of treatment related adverse events[Measured thoughout the study]
- Secondary Outcome Measures
Name Time Method Microbiological & Clinical Evaluation measured during double blind period and rescue period.[]